BPMC Blueprint Medicines Corp

Price (delayed)

$87.25

Market cap

$5.34B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.37

Enterprise value

$5.59B

Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, the company ...

Highlights
BPMC's gross profit is up by 33% year-on-year and by 20% since the previous quarter
Blueprint Medicines's revenue has increased by 22% YoY and by 15% QoQ
Blueprint Medicines's equity has shrunk by 75% YoY and by 36% QoQ
BPMC's debt is up by 37% year-on-year

Key stats

What are the main financial stats of BPMC
Market
Shares outstanding
61.23M
Market cap
$5.34B
Enterprise value
$5.59B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
40.61
Price to sales (P/S)
21.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.43
Earnings
Revenue
$249.38M
EBIT
-$487.22M
EBITDA
-$466.45M
Free cash flow
-$452.91M
Per share
EPS
-$8.37
Free cash flow per share
-$7.48
Book value per share
$2.15
Revenue per share
$4.12
TBVPS
$17.33
Balance sheet
Total assets
$1.05B
Total liabilities
$918.64M
Debt
$332.5M
Equity
$130.61M
Working capital
$593.47M
Liquidity
Debt to equity
2.55
Current ratio
3.76
Quick ratio
3.56
Net debt/EBITDA
-0.54
Margins
EBITDA margin
-187%
Gross margin
94.9%
Net margin
-203.3%
Operating margin
-195%
Efficiency
Return on assets
-45.3%
Return on equity
-191.6%
Return on invested capital
-43.6%
Return on capital employed
-58.4%
Return on sales
-195.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BPMC stock price

How has the Blueprint Medicines stock price performed over time
Intraday
-5.42%
1 week
-4.8%
1 month
-2.73%
1 year
99.2%
YTD
-5.41%
QTD
-8.02%

Financial performance

How have Blueprint Medicines's revenue and profit performed over time
Revenue
$249.38M
Gross profit
$236.58M
Operating income
-$486.28M
Net income
-$506.98M
Gross margin
94.9%
Net margin
-203.3%
BPMC's gross profit is up by 33% year-on-year and by 20% since the previous quarter
BPMC's net margin is up by 26% year-on-year and by 21% since the previous quarter
The operating margin has increased by 26% YoY and by 21% from the previous quarter
Blueprint Medicines's revenue has increased by 22% YoY and by 15% QoQ

Growth

What is Blueprint Medicines's growth rate over time

Valuation

What is Blueprint Medicines stock price valuation
P/E
N/A
P/B
40.61
P/S
21.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.43
Blueprint Medicines's EPS has increased by 10% YoY and by 9% QoQ
The price to book (P/B) is 112% higher than the last 4 quarters average of 19.2
Blueprint Medicines's equity has shrunk by 75% YoY and by 36% QoQ
The P/S is 66% below the 5-year quarterly average of 63.2 but 27% above the last 4 quarters average of 16.7
Blueprint Medicines's revenue has increased by 22% YoY and by 15% QoQ

Efficiency

How efficient is Blueprint Medicines business performance
BPMC's return on equity has dropped by 139% year-on-year and by 25% since the previous quarter
Blueprint Medicines's return on sales has increased by 26% YoY and by 20% QoQ
The ROIC has increased by 7% YoY and by 4% from the previous quarter
The company's return on assets fell by 4.4% YoY but it rose by 2.4% QoQ

Dividends

What is BPMC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BPMC.

Financial health

How did Blueprint Medicines financials performed over time
BPMC's total assets is 14% greater than its total liabilities
Blueprint Medicines's current ratio has decreased by 34% YoY and by 8% from the previous quarter
BPMC's quick ratio is down by 34% year-on-year and by 8% since the previous quarter
BPMC's debt is 155% greater than its equity
Blueprint Medicines's equity has shrunk by 75% YoY and by 36% QoQ
BPMC's debt to equity has surged by 55% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.